Impact of acute gain on clinical outcomes of patients treated with sirolimus-eluting stent: A sub-analysis study from the STLLR trial

Circulation Journal

Volumn 75, Issue 9, 2011, Pages 2113-2119

  Tahara, Satoko ^a   Bezerra, Hiram G ^a   Kyono, Hiroyuki ^a   Carrigan, Thomas ^a   Mehanna, Emile ^a   Wang, Wei ^a   Costa, Marco A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Acute gain; Diabetes mellitus; Drug eluting stent; Geographical miss

Indexed keywords

RAPAMYCIN;

ACUTE DISEASE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG ELUTING STENT; EPIDEMIOLOGICAL DATA; FEMALE; GEOGRAPHICAL MISS; HUMAN; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTION; PROSPECTIVE STUDY; RISK FACTOR; WEIGHT GAIN;

DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; SIROLIMUS;

EID: 80052145074     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0647     Document Type: Article

References (26)

1. Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Eur Heart J 2004; 25: 107-112.
2. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients. Circulation 2004; 109: 2273-2278.
3. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial. J Am Coll Cardiol 2005; 45: 1172-1179.
4. Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, Pache J, et al. Impact of diabetes mellitus on long-term outcomes in the drugeluting stent era. Am Heart J 2007; 154: 688-693.
5. Costa MA, Angiolillo DJ, Tannenbaum M, Driesman M, Chu A, Patterson J, et al. Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (Final results of the multicenter prospective STLLR Trial). Am J Cardiol 2008; 101: 1704-1711.
6. Sabaté M, Costa MA, Kozuma K, Kay IP, van der Giessen WJ, Coen VL, et al. Geographic miss: A cause of treatment failure in radiooncology applied to intracoronary radiation therapy. Circulation 2000; 101: 2467-2471.
7. Sianos G, Kay IP, Costa MA, Regar E, Kozuma K, de Feyter PJ, et al. Geographical miss during catheter-based intracoronary beta-radiation: Incidence and implications in the BRIE Study: Beta-Radiation In Europe. J Am Coll Cardiol 2001; 38: 415-420.
8. Kugelmass AD, Cohen DJ, Houser F, Mack M, Simon AW, Battaglia SL, et al. The influence of diabetes mellitus on the practice and outcomes of percutaneous coronary intervention in the community: A report from HCA database. J Invasive Cardiol 2003; 40: 418-423.
9. Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: Therapeutic options in patients with diabetes. J Am Coll Cardiol 2000; 36: 355-365.
10. Costa MA, Sabaté M, Angiolillo DJ, Hu P, Jimenez-Quevedo P, Corros C, et al. Relocation of minimal luminal diameter after bare metal and drug-eluting stent implantation: Incidence and impact on angiographic late loss. Catheter Cardiovasc Interv 2007; 69: 181-188.
11. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after artery injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993; 118: 344-349.
12. Huynh T, Eisenberg MJ, Deligonul U, Tsang J, Okrainec K, Schechter D, et al. Coronary stenting in diabetic patients: Results from the ROSETTA registry. Am Heart J 2001; 142: 960-964.
13. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-589.
14. Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 2004; 27: 990-994.
15. Van Belle E, Ketelers R, Bauters C, Périé M, Abolmaali K, Richard F, et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: A key determinant of survival in diabetics after coronary balloon angioplasty. Circulation 2001; 103: 1218-1224.
16. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, et al. Drug eluting and bare metal stents in people with and without diabetes: Collaborative network meta-analysis. BMJ 2008; 337: a1331.
17. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus results from the Massachusetts data analysis center registry. Circulation 2008; 118: 2277-2285.
18. Ortolani P, Balducelli M, Marzaroli P, Piovaccari G, Menozzi A, Guiducci V, et al. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions results from a real-world multicenter registry. Circulation 2008; 117: 923-930.
19. Nakamura M, Yokoi H, Hamazaki Y, Watarai M, Kijima M, Mitsudo K, et al. Impact of insulin-treated diabetes and hemodialysis on longterm clinical outcomes following sirolimus-eluting stent deployment: Insights from a sub-study of the Cypher Stent Japan Post-Marketing Surveillance (Cypher J-PMS) Registry. Circ J 2010; 74: 2592-2597.
20. Lee SP, Kim SY, Park KW, Shin DH, Kang HJ, Koo BK, et al. Long-term clinical outcome of chronic total occlusive lesions treated with drug-eluting stents: Comparison of sirolimus-eluting and paclitaxel-eluting stents. Circ J 2010; 74: 693-700.
21. Hong MK, Park SW, Lee CW, Kim YH, Song JM, Kang DH, et al. Relation between residual plaque burden after stenting and six-month angiographic restenosis. Am J Cardiol 2002; 89: 368-371.
22. Sakurai R, Ako J, Morino Y, Sonoda S, Kaneda H, Terashima M, et al; SIRIUS trial investigators. Predictors of edge stenosis following sirolimus-eluting stent deployment (A quantitative intravascular ultrasound analysis from SIRIUS trial). Am J Cardiol 2005; 96: 1251-1253.
23. Asano T, Kobayashi Y, Mintz GS, Ishio N, Fujimaki S, Ogawa Y, et al. Effect of plaque volume on subsequent vessel remodeling at edges of sirolimus-eluting stents. Am J Cardiol 2006; 98: 1041-1044.
24. Indolfi C, Torella D, Cavuto L, Davalli AM, Coppola C, Esposito G, et al. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic non-diabetic pancreatic islet-transplanted rats. Circulation 2001; 103: 2980-2986.
25. Park SH, Marso SP, Zhou Z, Foroudi F, Topol EJ, Lincoff AM. Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation 2001; 104: 815-819.
26. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373-1379.